Chemotherapy changes how thyroid hormones are carried in the blood, increasing a protein called TBG and reducing the availability of active thyroid hormone, which may contribute to fatigue and weight gain.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether chemotherapy consistently alters TBG and T3 uptake across studies and whether these changes correlate with symptoms like fatigue or weight gain.
A systematic review and meta-analysis of all prospective studies measuring TBG, T3 uptake, TSH, and free T4 in breast cancer patients before and after chemotherapy, including at least 15 studies with >1,000 total participants, stratified by chemotherapy regimen and menopausal status.
An RCT could determine whether specific chemotherapy agents directly cause TBG elevation and T3 uptake reduction, independent of estrogen changes.
A double-blind RCT of 200 premenopausal breast cancer patients randomized to receive chemotherapy with or without ovarian suppression (GnRH agonist), measuring TBG, T3 uptake, free T4, and TSH at baseline, mid-treatment, and 6 months to isolate chemotherapy effects from estrogen loss.
A prospective cohort could confirm the temporal sequence of TBG elevation and T3 uptake reduction following chemotherapy and correlate them with symptom onset.
A prospective cohort of 300 breast cancer patients, with monthly measurements of TBG, T3 uptake, free T4, TSH, estradiol, and SHBG from diagnosis through 12 months post-chemotherapy, to model the timing and predictors of thyroid transport changes.
A case-control study could identify whether patients with significant TBG elevation are more likely to report fatigue or weight gain than those with normal changes.
A matched case-control study comparing 100 patients with >30% TBG increase post-chemotherapy to 100 with <10% change, assessing fatigue severity, weight gain, and SHBG levels to determine if thyroid transport changes predict symptoms.
A cross-sectional study could estimate the prevalence of abnormal TBG and T3 uptake among breast cancer survivors who received chemotherapy.
A national survey of 2,500 breast cancer survivors, measuring current TBG, T3 uptake, and TSH levels and asking whether they received chemotherapy, adjusting for age, time since treatment, and hormone therapy use.